Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer : original article

enthalten in: Annals of oncology | 28 November 2022

von Geyer, C. | Garber, J. | Gelber, R. | +73